Targeting SMAD-Dependent Signaling: Considerations in Epithelial and Mesenchymal Solid Tumors

Area of Science:

• Molecular Biology
• Cancer Biology
• Pharmacology

Background:

• SMAD proteins are key intracellular mediators of transforming growth factor-β (TGF-β) signaling.
• TGF-β/SMAD pathway activity is complex, exhibiting both tumor-suppressive and tumor-promoting effects in epithelial cancers.
• The dual role of TGF-β/SMAD signaling complicates the development of targeted cancer therapies.

Purpose of the Study:

• To review preclinical studies on inhibitors targeting SMAD-regulating proteins.
• To evaluate the efficacy of these inhibitors in epithelial and mesenchymal compartments of solid tumors.
• To explore therapeutic strategies for overcoming the challenges posed by TGF-β/SMAD signaling in cancer.

Main Methods:

• Literature review of preclinical studies.
• Focus on inhibitors targeting SMAD-interacting and SMAD-regulating proteins, particularly enzymes.
• Analysis of studies evaluating efficacy in solid tumor models.

Main Results:

• Preclinical studies show varying efficacy of inhibitors targeting SMAD-regulating proteins.
• Enzymes involved in SMAD post-translational modifications are key targets.
• Inhibitor efficacy may differ between epithelial and mesenchymal states within tumors.

Conclusions:

• Targeting SMAD-regulating enzymes is a promising strategy for cancer therapy.
• Understanding the context-dependent roles of TGF-β/SMAD signaling is crucial for effective drug development.
• Further preclinical research is needed to optimize inhibitors for solid tumor treatment.